Boston Scientific Corporation vs Johnson & Johnson — Stock Comparison
Boston Scientific Corporation (BSX) and Johnson & Johnson (JNJ) are both listed on US exchanges. This page compares their Q·Score ratings, key fundamentals (P/E, margins, growth), and Wall Street analyst consensus side by side. Data sourced from Yahoo Finance and updated on each page load.
Boston Scientific Corporation scores ahead of Johnson & Johnson on Q·Score (8.5 vs 7.1 out of 10), led by Growth (8.8 vs 5.1) and Health (9.1 vs 6.5). Johnson & Johnson scores higher on Quality, reflecting stronger profitability and returns. Analyst consensus targets imply greater upside for BSX (+70.2%) than for JNJ (+10.7%).
Price Performance
Normalised to 100 at period start — shows relative performance.
Q·Score Breakdown
Clean balance sheet with low leverage (0.4× debt-to-equity).
High-quality business with 26% return on equity and 22% profit margins.
⚠ earnings contracting 53% year-over-year.
Analyst Consensus
Fundamentals
Frequently Asked Questions
BSX vs JNJ: which stock scores better overall?
Based on Q·Score, Boston Scientific Corporation (BSX) scores 8.5/10 versus Johnson & Johnson (JNJ) at 7.1/10. The Q·Score measures five dimensions: Quality, Health, Growth, Valuation, and Sentiment. For informational purposes only — not financial advice.
Which has better revenue growth: BSX or JNJ?
Boston Scientific Corporation (BSX) scores higher on Growth (8.8/10 vs 5.1/10). Boston Scientific Corporation reports revenue growth (11.6% YoY) while Johnson & Johnson reports (9.9% YoY). Growth scores reflect revenue and earnings momentum relative to sector peers.
Is BSX or JNJ more attractively valued?
Boston Scientific Corporation (BSX) scores higher on Valuation (8.6/10 vs 7.3/10). BSX trades at 12.2× P/E versus JNJ at 18.0×. Valuation is assessed using P/E ratio, analyst price targets, and 52-week range positioning relative to sector peers.
What do analysts say about BSX vs JNJ?
There are 30 analysts covering BSX with a consensus price target of $77.10, and 23 analysts covering JNJ with a consensus target of $252.87. Analyst consensus ratings are aggregated from Wall Street research and do not constitute investment advice.
Which is more profitable: BSX or JNJ?
Johnson & Johnson (JNJ) scores higher on Quality (9.3/10 vs 7.7/10). Net profit margin: BSX at 17.3%, JNJ at 21.8%. Quality scores reflect profit margins, return on equity, and free cash flow generation.
Which has stronger financial health: BSX or JNJ?
Boston Scientific Corporation (BSX) scores higher on Financial Health (9.1/10 vs 6.5/10). Market beta: BSX at 0.56, JNJ at 0.26. Health scores consider beta, debt-to-equity, and current ratio. All investments carry risk — this is not investment advice.
What are the market caps of BSX and JNJ?
Boston Scientific Corporation (BSX) has a market capitalisation of $67.3B, while Johnson & Johnson (JNJ) has a market cap of $549.8B. Market cap data is sourced from Yahoo Finance and reflects the most recent available figures.
Related Comparisons
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →